In this issue of LEAP you can read about our precision approach to an increasingly common illness, gout, to a rare illness linked to Sjögren’s, and to cancer patients who are developing some autoimmune-mediated complications. And we are especially excited to share with you a tremendous breakthrough in understanding how rheumatoid arthritis begins.
The study provides new evidence that a bacterium known to cause chronic inflammatory gum infections also triggers the inflammatory autoimmune response characteristic of chronic, joint-destroying rheumatoid arthritis (RA). The new findings have important implications for prevention and treatment of RA.
A new biomarker discovered using cutting-edge technologies is found in people who develop scleroderma and cancer within a short period of time.
Vaccines have been scientifically proven to save lives, increase lifespans, and maintain quality of life. Currently, only 39% of adults receive an annual flu shot. There are specific steps that can be taken to improve the vaccination rate. This is especially important in the immuno-compromised population.
On Saturday October 15, 2016, the Hopkins Rheumatology CARES (Centers Advancing RESearch) team was out in full force to support the “Myositis Run, Walk, n’ Roll 5k” event at Centennial Park in Columbia, MD.
This study explored the relationship between subtypes of demyelinating disorders and Sjogren’s syndrome. These findings help identify the spectrum of neurological disease directly attributable to SS.
Each year members of the Johns Hopkins Rheumatology team attend The American College of Rheumatology Conference. This year, we had the chance to connect with a few of our team members to discuss the research they presented at ACR 2016.
Patients and physicians came together in this international project to agree on what is critical to be measured in psoriatic arthritis clinical trials. This project was critical in defining what outcomes are important for both patients and their doctors.
The authors found that just very few patients reach durable remission, regardless of defining remission on-treatment or off-treatment. The higher the patients’ disease activity and treatment was when they entered our analysis, the lower was their chance of achieving remission.